| 查看: 770 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
材料工程085601，270求调剂
已经有24人回复
-
085404 293求调剂
已经有3人回复
-
调剂
已经有21人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有15人回复
-
08工科求调剂290分
已经有12人回复
-
286求调剂
已经有16人回复
-
材料类284调剂
已经有24人回复
-
考研调剂-材料类-284
已经有14人回复
-
327求调剂
已经有11人回复
-
一志愿985初试354分生物调剂
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
2007年一起玩耍的老虫子们，想死你们啦~~~出来冒个泡吧……
+1/168
-
西安石油大学新能源学院接收材料类、能源动力类、机械类、计算机类等专业专硕调剂生！
+1/88
-
河南师范大学材料学院招生调剂生
+2/68
-
青岛农业大学海洋学院招调剂硕士研究生
+1/51
-
浙江理工大学蒋仲庆 物理/新能源/材料 招9名
+2/48
-
生物化工学硕招收调剂
+1/41
-
2026-大连大学～六盘水师范学院联合培养硕士研究生，招收化学、环境等相关专业
+1/38
-
济南大学前沿交叉院 招化学学硕（物理可调）或 材料与化工专硕
+1/21
-
江西理工大学稀土学院-招收调剂硕士研究生
+1/20
-
佛山大学 动物科技学院 畜牧 欢迎广大学子报考！
+1/17
-
河北大学分析化学招收多名调剂考生
+1/12
-
化学与精细化工广东省实验室-汕头大学2026年联合培养硕士研究生调剂招生(材料与化工)
+1/11
-
南华大学资源与环境接受调剂，专业特色：“核”环保，有机会进入核相关企业工作。
+1/11
-
重庆大学微电子与通信工程学院张磊教授课题组招收2026级博士研究生（2026年9月入学）
+1/10
-
速报名！！！材料、化学等相关专业均可调剂
+1/10
-
Postdoc position in continuum mechanics of brain tissue at KTH in Stockholm
+1/9
-
济南大学物理科学与技术学院粒子物理方向招收调剂研究生
+1/7
-
26年申博自荐-计算机视觉
+1/7
-
杰青/长江团队招收硕士调剂
+1/5
-
一志愿211电子信息347求调剂
+1/4
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
|
b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. 术后48小时但不超过5天未使用抗生素所得的腹内脓肿（包括肝，脾）的患者，其脓肿是由于感染所引起的 |
8楼2011-01-12 10:42:52
